DPP-4 inhibitors mimic many of the actions ascribed to GLP-1 receptor agonists, including stimulation of insulin production and inhibition of glucagon secretion, and preservation of -cell mass by stimulating cell proliferation and inhibiting apoptosis [32]
They often mean more side effects without additional metabolic benefit
Patients typically report increased mental clarity, reduced fatigue, and a sense of physical lightness early in the protocol
National prescription drug spending grew 10% in 2024 alone, and GLP-1 medications are now estimated to account for 14% of all prescription drug spending in 2026
Unfortunately, anti-angiogenic monotherapies in melanoma did not show remarkable clinical responses and it has been suggested that vascular mimicry plays an important role in improving blood supply to the tumor to support its growth and dissemination (97, 98)
Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma